KemPharm, Inc. (NASDAQ:KMPH)‘s stock had its “buy” rating restated by equities research analysts at Canaccord Genuity in a research note issued on Monday. They presently have a $7.00 price target on the specialty pharmaceutical company’s stock. Canaccord Genuity’s price objective suggests a potential upside of 118.75% from the stock’s previous close.
Several other research analysts have also weighed in on the company. Oppenheimer Holdings, Inc. set a $13.00 target price on KemPharm and gave the stock a “buy” rating in a research report on Thursday, August 10th. Zacks Investment Research raised KemPharm from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. ValuEngine lowered KemPharm from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 8th. Roth Capital assumed coverage on KemPharm in a research report on Wednesday, June 28th. They issued a “buy” rating and a $8.00 target price on the stock. Finally, Royal Bank Of Canada reaffirmed a “buy” rating and issued a $8.00 target price on shares of KemPharm in a research report on Monday, May 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. KemPharm currently has an average rating of “Buy” and an average target price of $8.10.
Shares of KemPharm (NASDAQ:KMPH) remained flat at $3.20 during midday trading on Monday. 71,000 shares of the company’s stock traded hands. KemPharm has a 52-week low of $2.45 and a 52-week high of $5.40. The stock’s market cap is $46.90 million. The stock has a 50-day moving average price of $3.08 and a 200-day moving average price of $3.82.
KemPharm (NASDAQ:KMPH) last issued its quarterly earnings results on Thursday, August 10th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.19. Analysts predict that KemPharm will post ($2.72) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “KemPharm, Inc. (KMPH) Receives “Buy” Rating from Canaccord Genuity” was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/2887067/kempharm-inc-kmph-receives-buy-rating-from-canaccord-genuity.html.
In other news, CEO Travis C. Mickle bought 8,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 20th. The shares were acquired at an average cost of $3.45 per share, with a total value of $27,600.00. Following the transaction, the chief executive officer now owns 1,629,612 shares of the company’s stock, valued at approximately $5,622,161.40. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders purchased a total of 17,275 shares of company stock worth $51,808 over the last ninety days. Corporate insiders own 22.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. C WorldWide Group Holding A S increased its holdings in KemPharm by 110.1% in the 2nd quarter. C WorldWide Group Holding A S now owns 381,699 shares of the specialty pharmaceutical company’s stock valued at $1,527,000 after purchasing an additional 200,000 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in KemPharm in the 1st quarter valued at $647,000. Finally, Bank of New York Mellon Corp increased its holdings in KemPharm by 17.6% in the 1st quarter. Bank of New York Mellon Corp now owns 22,854 shares of the specialty pharmaceutical company’s stock valued at $112,000 after purchasing an additional 3,414 shares in the last quarter. Hedge funds and other institutional investors own 40.01% of the company’s stock.
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with MarketBeat.com's FREE daily email newsletter.